Table 5.

Clinical performance of p16/Ki-67 to detect CIN2+ (n = 124) or CIN3+ (n = 32) in women with HR-HPV–positive ASC-US or LSIL

SensitivitySpecificityPPVNPVReferral
p16/Ki-67
CIN2+85.5% (77.8–90.9)59.4% (53.3–65.1)48.4% (41.6–55.2)90.2% (84.7–93.9)54.48% (49.6–59.3)
CIN3+90.6% (73.8–97.5)48.6% (43.5–53.9)13.2% (9.2–18.6)98.4% (94.9–99.6)
HPV-HR+
CIN2+93.5% (87.3–97.0)31.9% (26.5–37.8)38.2% (32.7–43.9)91.2% (83.8–96.1)76.0% (71.6–79.9)
CIN3+96.9% (82.0–99.8)25.8% (21.5–30.7)10.2% (7.1–14.3)99.0% (93.5–99.9)
HPV16/18+
CIN2+47.6% (38.6–56.7)80.8% (75.5–85.2)52.7% (43.1–62.1)77.4% (72.1–82.0)28.0% (23.8–32.6)
CIN3+75.0% (71.3–80.3)76.1% (71.3–80.3)21.4% (14.5–30.4)97.2% (94.4–98.7)